Literature DB >> 11505212

Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma.

N Arslan1, S Ilgan, M Serdengecti, M A Ozguven, H Bayhan, K Okuyucu, S A Gulec.   

Abstract

The aims of this study were to evaluate the efficacy of an empirically determined "fixed" high ablative dose of radioiodine ((131)I) therapy and to determine the utility of ultrasonography (US) in dose determination. A retrospective analysis was performed of 242 thyroid cancer cases treated with "fixed" high-dose (131)I for ablation of thyroid remnants without a pre-ablative (131)I diagnostic scintigraphy or radioiodine uptake study. Treatment doses ranged from 1850 MBq (50 mCi) to 7.4 GBq (200 mCi). The selection of the treatment dose was based on the surgical and pathological findings as well as the remnant thyroid volume calculated by US. A successful ablation was defined as the absence of activity in the thyroid bed on subsequent imaging studies. Successful ablation was obtained in 218 of the 242 patients (90%). In 162 of the 218 patients (74.3%), successful ablation was achieved after a single (131)I treatment. The remnant thyroid volume calculated by US was significantly different (P=0.04) between those who were successfully ablated and those who were not. The total (131)I dose needed for successful ablation was significantly higher in males (P=0.003). Patients with higher post-operative thyroglobulin (Tgb) levels and patients with a higher stage of disease required higher doses (P=0.036 and P=0.021 respectively). Serum Tgb levels were under 10 ng.ml(-1) in 220 of the 242 patients (90%) following radioiodine ablation while not receiving L-thyroxine suppression. Nineteen patients (7.8%) showed metastases on post-therapy scan and successful treatment was achieved in 11 of 19 (57.8%). Four of the 19 patients with distant metastases (revealed on post-treatment scan) were found to have been given a treatment dose of less than 200 mCi based on the proposed empirical approach. These results indicate that "fixed" high-dose (131)I treatment is clinically feasible with an acceptable dose underestimation rate, and the utilization of US in the determination of the thyroid remnant volume provides more accurate and reproducible results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505212     DOI: 10.1097/00006231-200109000-00012

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Decreased uptake after fractionated ablative doses of iodine-131.

Authors:  Hurng-Sheng Wu; Huey-Herng Hseu; Wan-Yu Lin; Shyh-Jen Wang; Yao-Chi Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

2.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

3.  Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma.

Authors:  Seyfettin Ilgan; A Ozgur Karacalioglu; Yuksel Pabuscu; G Kaan Atac; Nuri Arslan; Emel Ozturk; Bengul Gunalp; M Ali Ozguven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

4.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

5.  Can shear wave elastography determine remnant thyroid tissue in the early postoperative period in patients with differentiated thyroid carcinoma?

Authors:  Emine Uysal; Gonca Kara Gedik; Mehmet Sedat Durmaz; Farise Yılmaz; Abdussamed Batur
Journal:  J Ultrasound       Date:  2021-04-05

6.  Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging.

Authors:  Guanghui Liu; Na Li; Xuena Li; Song Chen; Bulin Du; Yaming Li
Journal:  Biomed Res Int       Date:  2016-01-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.